CClinicalTrials.gg
CompletedNCT05703906TELEICTUSUpdated Jan 30, 2023

Teleneurorehabilitation for the Continuity of Care Post-stroke: a Multicentric Pilot Study

An interventional study of Telerehabilitation - VRRS Khymeia in Stroke, sponsored by IRCCS San Camillo, Venezia, Italy. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by IRCCS San Camillo, Venezia, Italy · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Mar 2018, registered Dec 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The main aim of this longitudinal, pilot study is to evaluate the feasibility of a multi-domain (i.e., motor, language and cognitive domains) telerehabilitation system using the Virtual Reality Rehabilitation System (VRRS, Khymeia) in patients with stroke. Furthermore, data on patients' needs and clinical data will be collected before and after treatment and then analyzed.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • Telerehabilitation
  • Feasibility
  • Virtual reality
03

In context

Stroke

7,287 studies on the registry are indexed under Stroke; 2,006 are open to participants now.

This study's enrollment of 84 is above the median of 50 across 5,370 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

IRCCS San Camillo, Venezia, Italy is the lead sponsor of 48 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Single ischemic stroke documented by CT/ MRI;
  • 2 to 18 months after the event.

Exclusion criteria

Exclusion Criteria:

  • medical history or presence of cognitive decline (MoCA\<17.54)
  • recent fractures
  • History of mental disorders (major depression, psychosis)
  • History/presence of other neurological disorders that may interfere with outcome
  • Presence of other internal pathologies that may interfere with outcome or treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Telerehabilitation

    All patients will receive a kit home-based consisting of a tablet home, an exercise equipment and access to a daily individualized training program based on their needs (i.e., motor, language and/or cognitive training programs). The exercise program and patients' sessions will be remotely supervised by therapists.

    Behavioral: Telerehabilitation - VRRS Khymeia

Interventions

  • BehavioralTelerehabilitation - VRRS Khymeia

    Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.

06

What researchers measure

Primary outcomes

  1. Feasibility of telerehabilitation system

    Feasibility will be measured by calculating the adherence to treatment (i.e. percentage of training sessions completed).

    Time frame: 6 weeks

  2. Feasibility of telerehabilitation system

    Feasibility will be measured with the Technology Acceptance Model (TAM), a specific questionnaire used to quantify the likelihood of technology acceptance, consisting of 12 items, six assessing perceived usefulness and six assessing perceived ease of use.

    Time frame: 6 weeks

  3. Feasibility of telerehabilitation system

    Feasibility will be measured with the System Usability Questionnaire (SUS), a 10 item questionnaire with five response options: from Strongly agree to Strongly disagree.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in measure of quality of life

    Quality of life will be measured by the Short-Form-36 Health Survey (SF-36), a questionnaire comprising 36 questions that cover 8 domains of health. Each of the 8 summed scores is linearly transformed onto a scale from 0 (negative health) to 100 (positive health) to provide a score for each domain. Each domain can be used independently.

    Time frame: Baseline up to 6 weeks

  2. Change in measure of quality of life

    Quality of life will be measured by the EuroQol-5 dimensions (EQ-5D), a questionnaire measuring 5 dimensions described by 3 possible levels of problems (i.e., none, mild-to-moderate, severe). Respondent's answers are translated into a preference-based score, yielding an index score based on a scale from 0.000 (death) to 1.000 (perfect health). The 5 dimensions can be converted to a single utility value (EQ-Index score).

    Time frame: Baseline up to 6 weeks

  3. Change in motor functions

    Change in motor functions will be assessed with the Fugl-Meyer Assessment (FMA), a stroke-specific scale which assesses the motor functioning in patients with post-stroke. There are 3 values for each of the 5 domain: 0 (severe impairment), 1 (moderate impairment), 2 (preserved function). The 5 domains assessed include: motor function (upper limb maximum score = 66; lower limb maximum score = 34), sensory function (maximum score = 24), balance (maximum score = 14), joint range of motion (maximum score = 44), joint pain (maximum score = 44), for an overall maximum score of 226 points.

    Time frame: Baseline up to 6 weeks

  4. Change in motor functions

    Assessed with the Nine hole pegboard test (NHPT), to measure finger dexterity. It is administered by asking the participant to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. Scores are based on the time taken to complete the activity, recorded in seconds.

    Time frame: Baseline up to 6 weeks

  5. Change in motor functions

    Assessed with the Box and block test (BBT). The patient has to carry as much cubes as possible, one by one, from a container to another one in one minute. The test is performed with both hands.

    Time frame: Baseline up to 6 weeks

  6. Change in motor functions

    Assessed with the Ashworth Spasticity Scale. The therapist evaluates the spasticity of the muscles. There are 5 values: 0 (no increase in muscle tone), 1 (slight increase in muscle tone), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone), 4 (affected part rigid in flexion or extension).

    Time frame: Baseline up to 6 weeks

  7. Change in linguistic functions

    Aachen Aphasie Test (AAT)

    Time frame: Baseline up to 6 weeks

  8. Change in cognitive functions

    Assessed with the Montreal Cognitive Assessment (MoCA), a cognitive screening tool comprising 16 items and 11 categories to assess multiple cognitive domains. The total possible score is 30, corresponding to a good performance.

    Time frame: Baseline up to 6 weeks

  9. Change in cognitive functions

    Assessed with the Bells test, a cancellation test that allows for a quantitative and qualitative assessment of visual neglect in the near extra personal space. The total number of cancelled bells is recorded as well as the time taken to complete. The maximum score is 35.

    Time frame: Baseline up to 6 weeks

  10. Change in cognitive functions

    Assessed with the verbal fluency test. Participants have to produce as many words as possible from a semantic and a phonemic category in 1 minute.

    Time frame: Baseline up to 6 weeks

  11. Change in Independence (Activities of Daily Living)

    Assessed with the Barthel Index (BI). It comprises 10 ADL/mobility activities, items are rated based on the amount of assistance required to complete each activity. Each item score ranges from 0 (dependent) to 10 (independent).

    Time frame: Baseline up to 6 weeks

  12. Change in behavior (depression)

    Assessed with the Beck Depression Inventory (BDI). Items are on a four-point scale that ranges from 0 to 3. Ratings are summed to provide a total score ranging from 0-63. Scores \>10 generally meet the threshold for a diagnosis of depression.

    Time frame: Baseline up to 6 weeks

  13. Change in caregiver burden

    Assessed with the Zarit Burden Interview (ZBI). It comprises 22 items with a score ranging from 0 ("never" to 4 ("nearly always"). Total scores are obrained by summing all items endorsed.

    Time frame: Baseline up to 6 weeks

  14. Satisfaction of the treatment

    Client Satisfaction Questionnaire, it consists of a 6 item questionnaire with five response options: from 0 to 4, where 0 reflects a negative response and 4 reflects a positive response.

    Time frame: 6 weeks

07

Study locations

1 site
  • IRCCS San Camillo Hospital
    Venice, 30126, Italy
08

References and documents

Publications

  • Cacciante L, Kiper P, Garzon M, Baldan F, Federico S, Turolla A, Agostini M. Telerehabilitation for people with aphasia: A systematic review and meta-analysis. J Commun Disord. 2021 Jul-Aug;92:106111. doi: 10.1016/j.jcomdis.2021.106111. Epub 2021 May 13. PubMed 34052617 ↗
  • Cacciante L, Pieta CD, Rutkowski S, Cieslik B, Szczepanska-Gieracha J, Agostini M, Kiper P. Cognitive telerehabilitation in neurological patients: systematic review and meta-analysis. Neurol Sci. 2022 Feb;43(2):847-862. doi: 10.1007/s10072-021-05770-6. Epub 2021 Nov 25. PubMed 34822030 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05703906
Lead sponsor
IRCCS San Camillo, Venezia, Italy
Collaborators
IRCCS Centro Neurolesi Bonino Pulejo, Fondazione Don Carlo Gnocchi Onlus, IRCCS Fondazione Istituto Neurologico Casimiro Mondino, Pavia (IT), IRCCS San Raffaele Roma, Istituto Clinico Humanitas
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Mar 16, 2018
Primary completion
Nov 30, 2021
Completion
Dec 31, 2021
Last update
Jan 30, 2023

Study contacts

Luisa Cacciante, MSc
principal investigator · IRCCS San Camillo Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion